W. Michael Flanagan Avidity Biosciences, Inc. (RNA) insider trading activity

W. Michael Flanagan is Chief Scientific Officer of Avidity Biosciences, Inc.. Currently has a direct ownership of 80,195 shares of RNA, which is worth approximately $2.66 Million. The most recent transaction as insider was on Jun 11, 2025, when has been sold 20,000 shares (Common Stock) at a price of $32.88 per share, resulting in proceeds of $657,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 80.2K

0% 3M change

57.97% 12M change

Total Value Held $2.66 Million

W. Michael Flanagan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 11 2025	SELL Open market or private sale	$657,600 $32.88 p/Share	20,000 Reduced 19.96%	80,195 Common Stock
Jun 11 2025	BUY Exercise of conversion of derivative security	$284,400 $14.22 p/Share	20,000 Added 16.64%	100,195 Common Stock
Mar 20 2025	SELL Open market or private sale	$365,886 $31.06 p/Share	11,780 Reduced 12.81%	80,195 Common Stock
Mar 11 2025	SELL Open market or private sale	$602,600 $30.13 p/Share	20,000 Reduced 17.86%	91,975 Common Stock
Mar 11 2025	BUY Exercise of conversion of derivative security	$284,400 $14.22 p/Share	20,000 Added 15.15%	111,975 Common Stock
Jan 21 2025	SELL Open market or private sale	$162,219 $28.6 p/Share	5,672 Reduced 5.81%	91,975 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	25,000 Added 20.38%	97,647 Common Stock
Dec 18 2024	SELL Open market or private sale	$416,153 $32.66 p/Share	12,742 Reduced 14.92%	72,647 Common Stock
Dec 11 2024	SELL Open market or private sale	$858,480 $35.77 p/Share	24,000 Reduced 21.94%	85,389 Common Stock
Dec 11 2024	BUY Exercise of conversion of derivative security	$539,280 $22.47 p/Share	24,000 Added 17.99%	109,389 Common Stock
Oct 01 2024	SELL Open market or private sale	$2,976,250 $47.62 p/Share	62,500 Reduced 42.26%	85,389 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$1,671,875 $26.75 p/Share	62,500 Added 29.71%	147,889 Common Stock
Sep 23 2024	SELL Open market or private sale	$1,098,750 $43.95 p/Share	25,000 Reduced 22.65%	85,389 Common Stock
Sep 19 2024	BUY Grant, award, or other acquisition	-	50,000 Added 33.85%	97,718 Common Stock
Sep 11 2024	SELL Open market or private sale	$4,500,317 $40.4 p/Share	111,394 Reduced 64.66%	60,871 Common Stock
Sep 11 2024	BUY Exercise of conversion of derivative security	$2,374,865 $24.61 p/Share	96,500 Added 46.78%	109,765 Common Stock
Jun 18 2024	SELL Open market or private sale	$395,447 $39.13 p/Share	10,106 Reduced 16.6%	50,765 Common Stock
Jun 17 2024	BUY Grant, award, or other acquisition	-	50,000 Added 39.76%	75,765 Common Stock
Jan 22 2024	SELL Open market or private sale	$41,826 $10.13 p/Share	4,129 Reduced 10.32%	35,871 Common Stock
Jan 20 2024	BUY Grant, award, or other acquisition	-	20,000 Added 49.64%	20,290 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	40,000 Added 49.82%	40,290 Common Stock

WMF

W. Michael Flanagan

Chief Scientific Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNA shares.

Notify only if

Value

Insider Trading

Get notified when an Avidity Biosciences, Inc. insider buys or sells RNA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Avidity Biosciences, Inc.

Track Activities on RNA

Account